{"groups":[{"description":"MOR00208:\n\nMOR00208 was administered via IV infusion at a dose of 12 mg/kg. For the first three cycles (Cycles 1 to 3) of the study each cycle consisted of a MOR00208 infusion on Day 1, Day 8, Day 15 and Day 22 of the cycle. Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter MOR00208 was administered on a bi-weekly (every 14 days) basis with infusions on Day 1 and Day 15 of each 28-day cycle.\n\nLEN:\n\nParticipants self-administered a starting dose of 25 mg oral LEN daily on Days 1-21 of each cycle, for up to 12 cycles in total. LEN dose could be modified in a de-escalating fashion or discontinued based upon clinical and laboratory findings. On days when both study drugs were given together, LEN was administered prior to MOR00208.","id":"FG000","title":"Treatment (MOR00208, Lenalidomide)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"16"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"42"}],"type":"Progressive disease/ Disease relapse"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"81"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"80"}],"type":"Received MOR00208 + LEN"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"Received MOR00208 Only"},{"achievements":[{"groupId":"FG000","numSubjects":"8"}],"type":"Completed: Participants Who Were Still on Treatment at EOS"},{"achievements":[{"groupId":"FG000","numSubjects":"73"}],"type":"Not Completed: Participants Who Were no Longer Receiving Treatment at EOS"},{"achievements":[{"groupId":"FG000","numSubjects":"8"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"73"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"The participants were enrolled into this study at sites in Hungary, Belgium, Czechia, France, Poland, Italy, Germany, Spain, United Kingdom, and the United States."}